US FDA grants priority review status to Johnson & Johnson’s nipocalimab BLA to treat generalized myasthenia gravis: Spring House, Pennsylvania Saturday, January 11, 2025, 12:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback